Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Common Equity (2016 - 2026)

Lineage Cell Therapeutics has reported Common Equity over the past 17 years, most recently at $52.7 million for Q1 2026.

  • For Q1 2026, Common Equity fell 32.14% year-over-year to $52.7 million; the TTM value through Mar 2026 reached $52.7 million, down 32.14%, while the annual FY2025 figure was $44.5 million, 42.15% down from the prior year.
  • Common Equity for Q1 2026 was $52.7 million at Lineage Cell Therapeutics, up from $44.5 million in the prior quarter.
  • Over five years, Common Equity peaked at $85.2 million in Q1 2022 and troughed at $20.8 million in Q3 2025.
  • A 5-year average of $65.2 million and a median of $69.0 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: rose 24.17% in 2024 and later crashed 67.9% in 2025.
  • Year by year, Common Equity stood at $71.9 million in 2022, then fell by 13.78% to $62.0 million in 2023, then rose by 24.17% to $77.0 million in 2024, then tumbled by 42.15% to $44.5 million in 2025, then grew by 18.29% to $52.7 million in 2026.
  • Business Quant data shows Common Equity for LCTX at $52.7 million in Q1 2026, $44.5 million in Q4 2025, and $20.8 million in Q3 2025.